NASDAQ$ARDX
Ardelyx Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2020.
Ardelyx reported $1.2 million in revenue for the quarter ended March 31, 2020. The company's cash, cash equivalents, and short-term investments totaled $223.2 million as of March 31, 2020. Net loss for the quarter was $22.4 million.
- Maintained a strong balance sheet with $223.2 million in cash, cash equivalents and short-term investments.
- Generated $1.2 million in revenue, primarily from collaborative development.
- Preparing NDA submission for Tenapanor for the control of serum phosphorus in mid-2020.
- Knight Therapeutics received approval from Health Canada for IBSRELA® for the treatment of IBS-C in adults.
Headline financials
Revenue & EPS history
Ardelyx · Revenue · Quarterly
$1.21M
Revenue by segment
Ardelyx · $35M total across 1 segment · Q4 2022
- Licensing Revenue$35M—100.0%
Forward guidance
Ardelyx is preparing a New Drug Application for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, which the company currently intends to submit to the U.S. Food and Drug Administration in mid-2020.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+0.0%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+5.2%
Avg return
30 days after
40%
20 / 50 earnings
Positive
+31.9%
Q1 2024
Best reaction
-24.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.2% | +12.2% | -4.7% | |
| Q4 2025 | -14.9% | -2.7% | -21.2% | |
| Q3 2025 | +18.6% | +18.8% | +15.8% | |
| Q1 2025 | -24.8% | -32.4% | -32.9% | |
| Q4 2024 | -10.1% | -18.6% | -19.3% | |
| Q3 2024 | +3.4% | -2.9% | -3.7% | |
| Q2 2024 | +9.0% | +9.5% | +11.4% | |
| Q1 2024 | +31.9% | +40.8% | +3.8% | |
| Q4 2023 | +2.1% | +13.8% | -9.4% | |
| Q3 2023 | +8.8% | +11.0% | +24.6% | |
| Q2 2023 | +4.2% | -2.3% | +25.5% | |
| Q1 2023 | +5.9% | -5.6% | -20.7% | |
| Q4 2022 | +30.8% | +34.9% | +64.0% | |
| Q3 2022 | +0.7% | -11.6% | +25.9% | |
| Q2 2022 | +11.5% | +14.9% | +42.5% | |
| Q1 2022 | -10.7% | -20.3% | -26.0% | |
| Q4 2021 | -7.6% | +17.0% | +37.1% | |
| Q3 2021 | -3.4% | -12.1% | +25.9% | |
| Q2 2021 | -1.3% | -9.9% | -10.5% | |
| Q1 2021 | +0.6% | +1.1% | +0.5% | |
| Q4 2020 | -4.8% | +4.5% | +14.2% | |
| Q3 2020 | -6.3% | +1.9% | +10.3% | |
| Q2 2020 | +1.4% | -2.6% | +0.7% | |
| Q1 2020 | +2.2% | +5.0% | -4.2% | |
| Q4 2019 | -7.3% | -9.1% | -12.6% | |
| Q3 2019 | +2.2% | +12.5% | +22.1% | |
| Q2 2019 | -3.8% | -5.1% | +108.1% | |
| Q1 2019 | -4.7% | -4.1% | -22.3% | |
| Q4 2018 | +8.0% | +9.7% | +9.0% | |
| Q3 2018 | -6.7% | -10.6% | -29.4% | |
| Q2 2018 | -7.1% | +0.0% | -7.1% | |
| Q1 2018 | +0.0% | +2.5% | -24.8% | |
| Q4 2017 | -5.0% | -4.5% | -6.2% | |
| Q3 2017 | +2.2% | +4.5% | +8.2% | |
| Q2 2017 | +11.0% | +17.2% | +29.9% | |
| Q1 2017 | -2.2% | -0.8% | -63.4% | |
| Q4 2016 | -2.4% | -1.1% | +13.7% | |
| Q3 2016 | +2.5% | +25.6% | +21.3% | |
| Q2 2016 | -0.8% | -1.9% | +5.8% | |
| Q1 2016 | -0.5% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | -4.4% | — | — | |
| Q2 2015 | -2.8% | — | — | |
| Q1 2015 | -0.4% | — | — | |
| Q1 2014 | -0.4% | — | — | |
| Q4 2014 | -5.2% | — | — | |
| Q3 2013 | -5.5% | — | — | |
| Q3 2014 | -5.5% | — | — | |
| Q2 2013 | -1.3% | — | — | |
| Q2 2014 | -5.2% | — | — | |
| Q4 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro